Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07135453 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Study acronym: Group 33/PCVs
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Jul 2026 to Jul 1, 2026v8
  2. Start date: May 2026 to Jul 2026v7
  3. Recruitment opened Start date: Mar 2026 to May 2026 · Site details revisedv6 Show 2 more changesShow less
    • Start date: Mar 2026 to May 2026
    • Site details revised
  4. Primary completion date: Aug 2026 to Mar 2027 Completion date: Aug 2026 to Aug 2027 · Start date: Jan 2026 to Mar 2026v5 Show 2 more changesShow less
    • Completion date: Aug 2026 to Aug 2027
    • Start date: Jan 2026 to Mar 2026
  5. Start date: Dec 2025 to Jan 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Enrollment target: 105 to 70 Start date: Sep 2025 to Dec 2025 · Study arms: 3 to 2v3 Show 2 more changesShow less
    • Start date: Sep 2025 to Dec 2025
    • Study arms: 3 to 2
  2. Site contact updatedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
Trial Details
NCT Number NCT07135453
Lead Sponsor University of Alabama at Birmingham
Collaborators: Merck Sharp & Dohme LLC
Conditions Vaccine, Pneumococcal Disease
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov